🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million infections per year. Particularly high rates are reported in Africa and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, the spread of superbugs and the very limited available drugs at this time.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, alternatively called Nuzolvence, was authorized by the US FDA in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts hope that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is also used to treat urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

As per results detailed in a major medical journal, the new drug cured more than 90% of cases of the STI. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The study involved hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have shared optimism. Access to a one-pill regimen such as this is described as a "critical tool" for managing the epidemic. This is viewed as essential to alleviate the strain of the illness for people and to prevent the spread of untreatable gonorrhoea around the world.